Registry to Measure the Impact of Adding Genomic Testing
Terminated
- Conditions
- Prostate Cancer
- First Posted Date
- 2015-05-27
- Last Posted Date
- 2017-09-05
- Lead Sponsor
- Myriad Genetic Laboratories, Inc.
- Target Recruit Count
- 116
- Registration Number
- NCT02454595
- Locations
- 🇺🇸
Intermountain Healthcare, Salt Lake City, Utah, United States
Open Registry Measuring Impact of Genomic Testing on Treatment Decision After Biopsy in Newly Diagnosed Prostate Cancer Patients
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2014-08-06
- Last Posted Date
- 2017-09-05
- Lead Sponsor
- Myriad Genetic Laboratories, Inc.
- Target Recruit Count
- 274
- Registration Number
- NCT02209584
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-up
Terminated
- Conditions
- Lung CancerLung AdenocarcinomaNSCLC
- First Posted Date
- 2014-04-24
- Last Posted Date
- 2017-09-05
- Lead Sponsor
- Myriad Genetic Laboratories, Inc.
- Target Recruit Count
- 227
- Registration Number
- NCT02121925
Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006)
Terminated
- Conditions
- NSCLCNSCLC AdenocarcinomaLung Cancer
- First Posted Date
- 2014-04-24
- Last Posted Date
- 2017-09-05
- Lead Sponsor
- Myriad Genetic Laboratories, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT02121899
Open Registry Measuring Impact of Genomic Testing on Treatment of Prostate Cancer Patients
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2015-06-02
- Lead Sponsor
- Myriad Genetic Laboratories, Inc.
- Target Recruit Count
- 1270
- Registration Number
- NCT01954004
Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6
Phase 4
Terminated
- Conditions
- Colorectal Cancer, Metastatic
- Interventions
- Other: Standard of careOther: Pharmacokinetic 5-FU dose adjustment using OnDose® assay
- First Posted Date
- 2011-11-09
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- Myriad Genetic Laboratories, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT01468623
© Copyright 2025. All Rights Reserved by MedPath